| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b75d73e09e4f6448a86285fc5254e5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6861 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-21 |
| filingDate |
2016-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6f4be7fcb6f24bd1f95fe185b30d857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e5b190749d65e1df32abbb7cd49c62f |
| publicationDate |
2018-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3268040-A1 |
| titleOfInvention |
Methods of treatment for epcam positive bladder cancer |
| abstract |
The present disclosure provides compositions and methods for treatment of bladder cancer. The methods include administering an immunoconjugate having a binding protein that specifically binds to Ep-CAM and a toxin to a subject in need of treatment for bladder cancer. In one aspect, the present disclosure provides methods for treating bladder cancer in a subject in need thereof, wherein the methods comprise administering to the subject an immunoconjugate, and wherein the administration is sufficient to result in event-free survival of the subject. In some embodiment's, the administration is sufficient to result in event-free survival of the subject for at least 12 months following the first dose of the the immunoconjugate. In some embodiment's, the administration is sufficient to result in event free survival of the subject for at least about 18 months following the first dose of the immunoconjugate. |
| priorityDate |
2015-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |